The Canadian/US Integrative Oncology Study (CUSIOS): Advanced Integrative Oncology Treatment for Patients with Advanced Stage Cancer: A Prospective Outcomes Study

An observational study describing the three-year survival outcome of advanced stage cancer patients receiving care at one of the participating integrative oncology (AIO) clinics in North America. Co-Principal Investigators: Dugald Seely, ND, MSc, FABNO – Canadian College of Naturopathic Medicine Leanna J. Standish, ND, PhD, LAc, FABNO – Bastyr University

The Bastyr Integrative Oncology Outcomes Study: Evaluating Outcomes in Patients Receiving Integrative Oncology Care (BOS)

This observational study seeks to describe the outcomes for individuals who choose to receive integrative oncology care. We will report on clinical outcomes of our patients in terms of whether cancer comes back after treatment (recurrence rates) and survival. We are also interested in identifying therapies recommended to our patients and length of hospice stay when applicable. You will not directly benefit from the study, but information gathered during the course of this study may help us begin to assess the longer-term effects of integrative naturopathic, traditional, Chinese and palliative medicine on cancer patients. To read more about this study, please click on the study title above.

Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study

PURPOSE: This NIH-NCCAM funded epidemiologic research is being conducted as an observational prospective case-control study of the use of Complementary and Alternative Medicine (CAM) and Integrative Oncology (IO) and their effects on breast cancer patients in community settings. Clinicaltrials.gov: NCT-1366248. This study is ongoing but not recruiting new participants.

CAM Therapies in Colon Cancer

Bastyr Integrative Oncolgy Reserch Center (BIORC) is actively recruiting participants with colon cancer at any stage to take part in an observational research study. By studying how cancer reacts when treated with naturopathic medicine, traditional Chinese medicine, acupuncture and mind-body therapies, we hope to uncover complementary and alternative medical (CAM) solutions that help patients fight cancer while also managing the effects of chemotherapy.

Estrogen plus progestin and colorectal cancer in postmenopausal women.



Although the Women's Health Initiative (WHI) trial of estrogen plus progestin in postmenopausal women identified more overall health risks than benefits among women in the hormone group, the use of estrogen plus progestin was associated with a significant decrease in the risk of colorectal cancer. We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants.

The use of complementary and alternative medical providers by insured cancer patients in Washington State.



Insurance coverage of complementary and alternative medicine (CAM) is expanding. However, to the authors' knowledge, little is know concerning CAM utilization among cancer patients under the insurance model of financing. In this study, the authors evaluated CAM provider utilization by cancer patients in a state that requires the inclusion of alternative practitioners in private, commercial insurance products.


An analysis was carried out of year 2000 claims data from two large Washington State insurance companies.

Breast cancer and the immune system

This article reviews the evidence that the functioning of both the innate and the adaptive immune system plays a role in preventing relapse in women with breast cancer. Lymphocytes, including T cells, T regulatory cells, and natural killer cells, and their cytokine release patterns are implicated in both primary prevention and recurrence of breast cancer. Cancer prognosis may be related to immune system functional status. The hypothesis that the immune system has a causal role in breast cancer etiology is supported by epidemiologic, preclinical, and clinical research.

Trametes versicolor mushroom immune therapy in breast cancer

Data from multiple epidemiologic and clinical studies on immune effects of conventional cancer treatment and the clinical benefits of polysaccharide immune therapy suggest that immune function has a role in breast cancer prevention. Immune therapy utilizing the polysaccharide constituents of Trametes versicolor (Tv) as concurrent adjuvant cancer therapy may be warranted as part of a comprehensive cancer treatment and secondary prevention strategy.